PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Celeros, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Celeros Equipment Selected by Sanofi Pasteur for New Vaccine Production Facility - Celeros, Inc., announced that it was selected by Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, as a supplier of advanced centrifuge separations equipment for a new vaccine facility in Marcy l’Etoile, France
Celeros Equipment Selected by Sanofi Pasteur for New Vaccine Production Facility

 

NewswireToday - /newswire/ - Foxboro, MA, United States, 2011/01/04 - Celeros, Inc., announced that it was selected by Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, as a supplier of advanced centrifuge separations equipment for a new vaccine facility in Marcy l’Etoile, France.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Celeros was selected based on their breakthrough technologies and expertise in solid-liquid separations. The equipment is recognized as a new generation centrifuge system of industrial interest. Through a tight collaboration with Sanofi Pasteur this new equipment should be implemented in one of Sanofi Pasteur cutting-edge vaccine production facilities in Marcy l’Etoile.

The new automated centrifuges from Celeros, once qualified, will enable Sanofi Pasteur to achieve a closed system process approach and a high level of automation with improved productivity.

"Our respective organizations have a similar focus on process improvements to drive quality and productivity," said Greg Cybulski, Director of Sales and Marketing for Celeros. "As with all our partners, we are pleased to be working closely with Sanofi Pasteur to help them achieve their goals."

Among the new equipment purchased by Sanofi Pasteur are the latest version, midsized, Celeros Automated Piston Discharge (APD), high performance centrifuges, capable of precise, low moisture solids recovery, superior to disk machines.

About Sanofi Pasteur

Sanofi Pasteur (sanofipasteur.com, sanofipasteur.us), the vaccines division of Sanofi-Aventis Group, provided more than 1.6 billion doses of vaccine in 2009, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development.

About Celeros, Inc.

Celeros, Inc. (celerosinc.com) creates business advantages for biotech and pharmaceutical organizations by delivering practical and sustainable innovation to enable significant advancements in process yield and cost control. Pioneering patented Automated Discharge technology for demanding Biotech and pharmaceutical separation applications, Celeros’ innovations provide an enduring platform for customer success. Celeros is driving process improvement and operational excellence for customers worldwide.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Celeros, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Celeros Equipment Selected by Sanofi Pasteur for New Vaccine Production Facility

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Greg Cybulski - Celerosinc.com 
508-698-3080 greg.cybulski[.]celerosinc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Celeros, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Celeros, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  SKS Media | SKS Associates Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)